Sep. 17, 2012 (China Knowledge) - Taizhou Huaxin Medicine Investment Ltd, which is engaged in medicine development, real estate and infrastructure construction in Taizhou
Province, has announced it will issue RMB 950 million in medium-term notes with a maturity of five years in the interbank market on Sep 24.
The company said in a statement that the notes will be issued at face value, and the coupon rate determined in the process of book-building.
Both value and payment due date is set on Sep 26, and the to-be-issued notes tradable Sep 27.
All the proceeds from the issue will be used to repay bank loans, said the issuer.
Shanghai Brilliance Credit Rating & Investors Service Co Ltd has rated the issuer and notes AA and AA, respectively.
Huaxia Bank Co Ltd<600015
> has been hired as lead underwriter and bookrunner. Shanghai Pudong Development Bank Co Ltd<600000
> will be joint lead underwriter for the offering.